BIO announces presenters for BIO CEO and Investor Conference.

Press Release Summary:



BIO announced preliminary list of presenting companies for 17th Annual BIO CEO & Investor Conference to be held Feb 9–10, 2015. Presenting companies are hand-selected for event, and consist of mid-to-large cap established public companies from around the globe. Participating companies typically have a clinical stage program focused on therapeutics, molecular diagnostics, or a platform technology, as well as an upcoming clinical, regulatory, or corporate catalyst.



Original Press Release:



More Than 150 Companies Expected to Present at the 17th Annual BIO CEO & Investor Conference



Companies to share their stories with top public and venture capital investors



BIO CEO & Investor Conference 2015



WASHINGTON -- The Biotechnology Industry Organization (BIO) today announced the preliminary list of presenting companies for the 17th Annual BIO CEO & Investor Conference to be held February 9-10, 2015 in New York City. Presenting companies are hand-selected for the event, and consist of a selection of mid-to-large cap established public companies from around the globe. The participating companies typically have a clinical stage program focused on therapeutics, molecular diagnostics, or a platform technology, as well as an upcoming clinical, regulatory, or corporate catalyst.



“The industry is currently experiencing another banner year for biotech IPOs. With 79 IPOs year to date, we are nearly double where we were this time last year. We are thrilled to be hosting one-quarter of the 2014 IPO class as presenting companies at the BIO CEO & Investor Conference”



“The industry is currently experiencing another banner year for biotech IPOs. With 79 IPOs year to date, we are nearly double where we were this time last year. We are thrilled to be hosting one-quarter of the 2014 IPO class as presenting companies at the BIO CEO & Investor Conference,” said BIO President and CEO Jim Greenwood.



In addition, to spotlight both established public and late-stage private companies at the BIO CEO & Investor Conference, BIO hosted the Buzz of BIO competition. This contest recognizes highly innovative companies in the biotech sector. A new element to this year’s CEO conference and modeled after the Buzz of BIO contest held in conjunction with the BIO International Convention, the campaign drew 18 nominees and pulled in nearly 800 votes. Winners are given the opportunity to present their story to industry leaders at the event. The winners are:



Most Distinguished Public Company

Synthetic Biologics, Inc. is a clinical-stage biotechnology company developing pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome.



Most Promising Private Company

Diffusion Pharmaceuticals is a clinical-stage biotech company developing new, small-molecule drugs that help regulate the movement of oxygen into tissue by a novel mechanism of action.



Below is the full list of companies planning to present at this year’s conference:



Public Companies:



AcelRx Pharmaceuticals

Actinium Pharmaceuticals

Advaxis

Aerie Pharmaceuticals

Affimed Therapeutics

Agenus

Akebia Therapeutics

Alkermes

Amarantus Bioscience

Anavex Life Sciences Corp.

Apricus Biosciences

Aquinox Pharmaceuticals

Aradigm Corporation

Arena Pharmaceuticals

Argos Therapeutics

Athersys Inc.

Aurinia Pharmaceuticals

Biocept

BioLineRx

Biota Pharmaceuticals

Biotie Therapies

Biotron

BrainStorm Cell Therapeutics

Cancer Genetics

Can-Fite BioPharma

Cara Therapeutics

CASI Pharmaceuticals

Celator Pharmaceuticals

Celladon Corporation

Cellectar Biosciences

CEL-SCI Corporation

Celsus Therapeutics

Cerulean Pharma

Chimerix

Cleveland BioLabs

Codexis

Columbia Laboratories

Conatus Pharmaceuticals

ContraFect Corporation

Corbus Pharmaceuticals

Cortendo AB

Curis, Inc

Cyclacel Pharmaceuticals

Cymabay Therapeutics

Cytokinetics

DARA BioSciences

Dipexium Pharmaceuticals

DURECT Corporation

Eleven Biotherapeutics

EnteroMedics

Exelixis

Galena Biopharma

GENFIT

Genocea Biosciences

GenSpera

Geron Corporation

GlobeImmune

GlycoMimetics

Heat Biologics

Horizon Pharma

Idera Pharmaceuticals

Immune Pharmaceuticals

ImmunoCellular Therapeutics

Immunovaccine

Inovio Pharmaceuticals

KaloBios Pharmaceuticals

Kite Pharma

Lexicon Pharmaceuticals

Macrocure Ltd.

Marinus Pharmaceuticals

Mast Therapeutics

Matinas BioPharma

NanoViricides Inc.

Navidea Biopharmaceuticals

NeoStem

Neovacs SA

NephroGenex

Neuralstem

Newron Pharmaceuticals S.p.A.

Northwest Biotherapeutics

Ocata Therapeutics

Ocular Therapeutix

OHR Pharmaceutical

OncoMed Pharmaceuticals

Onconova Therapeutics

OncoSec Medical

Opexa Therapeutics

Oragenics

OXiGENE

PAION AG

Palatin Technologies Inc.

PDL BioPharma

Pfenex Inc.

Probiodrug AG

Progenics Pharmaceuticals

Prometic LifeSciences

Proteon Therapeutics

Provectus Biopharmaceuticals

pSiVida

Recro Pharma

Regado Biosciences

Regulus Therapeutics

Relypsa

RestorGenex

Resverlogix

Rexahn Pharmaceuticals

Rigel Pharmaceuticals

RXi Pharmaceuticals

Santhera Pharmaceuticals

SciClone Pharmaceuticals

Selvita S.A.

Soligenix

StemCells Inc.

Stemline Therapeutics

Synergy Pharmaceuticals

Synta Pharmaceuticals

Synthetic Biologics

Tetraphase Pharmaceuticals

TG Therapeutics

TiGenix N.V.

Tonix Pharmaceuticals

Trevena

Trillium Therapeutics

uniQure N.V.

Verastem

Versartis

ZIOPHARM Oncology



Private Companies:



Adaptimmune

Anergis SA

BeiGene

BioXcel

Diffusion Pharmaceuticals

Dimension Therapeutics

G1 Therapeutics

Genervon Therapeutics

Hydra BioSciences

Isarna Therapeutics

Juventas Therapeutics

Kinemed

MaxCyte

Mirna Therapeutics

Nanotherapeutics, Inc.

Neurovance Inc.

Polynoma LLC

Spark Therapeutics

Spring Bank Pharmaceuticals

Sutro Biopharma

Syndax Pharmaceuticals

Targazyme, Inc.

Theraclone Sciences



To learn more about the BIO CEO & Investor Conference, including registration, programming and partnering information, please visit here.



Complimentary registration is available to qualified institutional (buy and sell-side), private equity or venture capital investors. Qualified investors are defined as institutional, private equity, angel and venture investors with funds on-hand, whose primary activity is direct investment in research and development companies. Equity research analysts from investment banking institutions and buy-side analysts also qualify as investors.



Media registration is complimentary for credentialed members of the media. All registrations are subject to verification of credentials. To complete your registration, visit here.



BIO is pleased to recognize the leadership provided by the BIO CEO & Investor Conference sponsors including supporting banks BMO Capital Markets, HC Wainwright & Co., JMP Securities, Lazard and ROTH Capital Partners, LLC.



About BIO

BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO's blog chronicling “innovations transforming our world” and the BIO Newsletter is the organization’s bi-weekly email newsletter. Subscribe to the BIO Newsletter.



Upcoming BIO Events



BIO CEO & Investor Conference

February 9-10, 2015

New York City, NY



BIO-Europe Spring

March 9-11, 2015

Paris, France



BIO Asia International Conference

March 24-25, 2015

Tokyo, Japan



BioEquity Europe

May 19-20, 2015

Vienna, Austria



BIO International Convention

June 15-18, 2015

Philadelphia, PA



Contacts

Biotechnology Industry Organization

Abigail Hirsch, 202-962-9235

Web: www.bio.org

Blog: www.biotech-now.org

Twitter: @IAmBiotech

All Topics